Open AccessSpontaneous pneumothorax during nintedanib therapy in patients with systemic sclerosis‐associated interstitial lung disease
Author(s) -
Sumi Toshiyuki,
Uehara Hirofumi,
Tada Makoto,
Keira Yoshiko,
Kamada Koki,
Shijubou Naoki,
Yamada Yuichi,
Nakata Hisashi,
Mori Yuji,
Chiba Hirofumi
Publication year - 2021
Publication title -
respirology case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.304
H-Index - 9
ISSN - 2051-3380
DOI - 10.1002/rcr2.716
Subject(s) - nintedanib , medicine , interstitial lung disease , pneumothorax , refractory (planetary science) , lung function , lung , complication , scleroderma (fungus) , idiopathic pulmonary fibrosis , surgery , pathology , physics , astrobiology , inoculation
Interstitial lung disease (ILD) is a common complication of systemic sclerosis (SSc). Nintedanib, an antifibrotic drug, has recently been approved for treating SSc‐ILD. Although there have been no reports suggesting the development of pneumothorax with nintedanib use, its safety in patients with impaired lung function is unclear. We observed the development of refractory spontaneous pneumothorax during nintedanib therapy in two patients with SSc‐ILD and impaired lung function. Nintedanib use for SSc‐ILD, an extensive disease, may therefore increase the risk of pneumothorax. In addition, pneumothorax is more likely to be refractory in these cases; initiation of nintedanib treatment and follow‐up should be considered carefully.